Four signals from the first half
The headline is not a collapse in RCM dealmaking. It is a change in where investors and strategic buyers are placing bets.
RCAI tracked eight H1 2026 funding rounds versus five in H1 2025, a 60% increase. Yet disclosed funding fell from $361.7M to $212M and the median round fell from $52.5M to $17M. More companies got funded; capital was spread across more focused workflow bets.
Adonis, Amperos, Anomaly, Commure, Joyful, Procode and other funded platforms explicitly center automation, agentic workflows, payer intelligence or AI-driven revenue operations. Investors are underwriting execution, not dashboards.
Strategic deals such as Zelis–Rivet, EnableComp–H/ROI, Knowtion–revly, TELCOR–Sample, Med-Metrix–Vitalware and Innovaccer–CaduceusHealth add specific execution layers: analytics, clinical denials, reimbursement optimization, workflow automation, revenue integrity and full-stack operations.
IKS, Med-Metrix, Carlyle/Knack/Equalize, Knowtion, Zelis and other scaled buyers are assembling broader RCM operating systems. The strategic question is increasingly not “software or services?” but “who can own the workflow end to end?”
Funding: more rounds, smaller median
Disclosed funding only. M&A consideration is excluded from this comparison because most strategic transaction values are undisclosed and not comparable to financing proceeds.
Median disclosed round: $52.5M. Commure’s $200M growth financing was the largest tracked financing in the cohort.
Median disclosed round: $17M. Capital spread across AI RCM, payer intelligence, contract intelligence, denials and revenue recovery.
Selected H1 2026 transactions
The public report shows the pattern. The live database and CSV workflow are available through the Deal Tracker and RCAI Pro.
| Date | Transaction | Type | Value | Strategic signal |
|---|---|---|---|---|
| Jan 12 | Zelis acquires Rivet | M&A | Undisclosed | Revenue-cycle analytics + payer/provider payments |
| Mar 17 | Turquoise Health Series C | Funding | $40M | Contracts, pricing and payment infrastructure |
| Mar 25 | Adonis Series C | Funding | $40M | AI orchestration for revenue operations |
| Apr 16 | Joyful Health Series A | Funding | $17M | Financial system of record + revenue recovery |
| Apr 23 | IKS agrees to acquire TruBridge | M&A | $557M | EHR + RCM backbone for rural/community hospitals |
| May 13 | Anomaly raises extension | Funding | $17M | Payer intelligence expands into managed care |
| Jun 4 | Med-Metrix agrees to acquire Vitalware | M&A | $147M | Revenue integrity + workflow software |
| Jun 17 | Thoreau invests in Ensemble | Growth | Undisclosed | Scaled end-to-end managed RCM platform |
Want the rows behind the report?
RCAI Pro turns the public research into a working dataset: CSV export, buyer and investor context, company dossiers, funding histories and Ask RevCycleAI. Use it to screen the market instead of rebuilding the database yourself.
Get RCAI Pro →Open Deal TrackerWhat the backfill changed
Why data hygiene matters before calling a market trend.
The original structured ledger undercounted both periods. The audit reconciled the live Deal Tracker against RCAI’s own Funding Watch, primary company announcements and SEC filings. It also moved two 2026 transactions into H1 based on their original announcement dates rather than later closing dates.
- IKS / TruBridge: definitive agreement announced April 23, 2026; later closed July 9. The report counts April 23.
- Med-Metrix / Vitalware: definitive agreement announced June 4, 2026; later closed July 31. The report counts June 4.
- Thoreau / Ensemble: corrected from an earlier rumor framing to the June 17 announced strategic growth investment; terms were undisclosed.
- Funding reconciliation: Adonis, Joyful, Anomaly and Turquoise were already covered in RCAI research but missing from the structured ledger. They are now backfilled.
Methodology
Designed for repeatable H2 and annual reporting.
- This analysis covers RCAI-tracked notable RCM transactions, not every healthcare or eHealth transaction in the market.
- Transactions are dated to the earliest verifiable public announcement; closing dates are used only when an earlier transaction announcement is unavailable.
- Funding is included when the company or financing has a material revenue-cycle, reimbursement, claims, payment, denials, coding, prior-auth or related financial-workflow thesis.
- Funding-dollar comparisons include disclosed financing proceeds only. M&A transaction values are intentionally kept separate because most are undisclosed and valuations are not the same as capital invested.
- Sources prioritize company announcements and SEC filings. The live ledger remains subject to correction as additional primary evidence becomes available.